Get the Stockscreener App
2.14
2.39%
0.05
Pre-market:
2.17
0.03
+1.40%
Kiora Pharmaceuticals Inc stock is traded at $2.14, with a volume of 35,320.
It is up +2.39% in the last 24 hours and up +8.63% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.09
Open:
$2.13
24h Volume:
35,320
Relative Volume:
0.87
Market Cap:
$7.87M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.1491
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
-1.83%
1M Performance:
+8.63%
6M Performance:
-26.96%
1Y Performance:
-42.01%
1-Day Range:
$2.025
$2.20
1-Week Range:
$2.02
$2.3199
52-Week Range:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.14 | 7.69M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Is Kiora Pharmaceuticals Inc still a buy after recent gains2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Kiora Pharmaceuticals adds retina specialist to advisory board By Investing.com - Investing.com Canada
Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan
Update Recap: Does Kiora Pharmaceuticals Inc have pricing power2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Recap: Does Kiora Pharmaceuticals Inc have consistent dividend growthMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upsideDividend Aristocrats List & Outperform With Our Smart Trading Calculator - Bollywood Helpline
Institution Moves: Can ADS TEC Energy PLC Equity Warrant deliver alphaEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Fund Flows: Is Kiora Pharmaceuticals Inc stock supported by innovation pipeline2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - Bộ Nội Vụ
Will Kiora Pharmaceuticals Inc. stock deliver better than expected guidanceMarket Movers & Weekly Stock Performance Updates - Улправда
Will Kiora Pharmaceuticals Inc. (7EY) stock announce a stock splitTrade Ideas & Risk Controlled Daily Plans - Улправда
Why Kiora Pharmaceuticals Inc. (7EY) stock trades below fair valueJuly 2025 Closing Moves & Weekly Market Pulse Updates - Улправда
Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Trend Recap & Weekly Consistent Profit Watchlists - ulpravda.ru
Kiora Pharmaceuticals, Inc.Common Stock (NQ: KPRX - FinancialContent
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World
Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn
Will Kiora Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trade Review & Target Return Focused Stock Picks - Улправда
Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Weekly Stock Analysis & Free Risk Controlled Daily Trade Plans - Улправда
Will Kiora Pharmaceuticals Inc. stock rally after Fed decisionsJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Kiora Pharmaceuticals Inc. stock overvalued by current metrics2025 Stock Rankings & Verified Momentum Stock Ideas - Улправда
How Kiora Pharmaceuticals Inc. stock reacts to bond yields2025 Volatility Report & Safe Entry Trade Reports - DonanımHaber
Why analysts upgrade Kiora Pharmaceuticals Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда
How Kiora Pharmaceuticals Inc. stock benefits from global expansionStock Surge & Free Growth Oriented Trading Recommendations - DonanımHaber
Can Kiora Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website - TMX Newsfile
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - TMX Newsfile
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study - TMX Newsfile
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years - TMX Newsfile
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million - TMX Newsfile
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini - TMX Newsfile
Aug Decliners: Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Swing Trade & Intraday High Probability Alerts - Улправда
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave? - FinancialContent
Kiora Pharmaceuticals Earnings Notes - Trefis
Aug Rallies: How geopolitical tensions affect Kiora Pharmaceuticals Inc stock2025 Bull vs Bear & Community Consensus Trade Signals - moha.gov.vn
Kiora Pharmaceuticals, Inc. (KPRX) AI-Powered Stock Analysis - Meyka
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.5% – Should You Sell? - Defense World
Will Kiora Pharmaceuticals Inc. (7EY) stock beat Nasdaq index returnsQuarterly Trade Report & Proven Capital Preservation Methods - Newser
How Kiora Pharmaceuticals Inc. (7EY) stock reacts to new regulationsJuly 2025 Recap & Expert Approved Momentum Ideas - Newser
Is Kiora Pharmaceuticals Inc. (7EY) stock cheap vs fundamentalsJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - Newser
Will Kiora Pharmaceuticals Inc. stock benefit from commodity prices2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Kiora Pharmaceuticals receives new patent for KIO-100 formulations By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals receives new patent for KIO-100 formulations - Investing.com
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - TMX Newsfile
What drives Kiora Pharmaceuticals Inc stock priceConsumer Goods Stocks & Free Daily Top Stock Picks for All Investors - earlytimes.in
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema? - MSN
What analyst consensus implies for Kiora Pharmaceuticals Inc. (7EY) stock2025 Market WrapUp & High Accuracy Trade Signal Alerts - newser.com
Can Kiora Pharmaceuticals Inc. stock resist sector downturnsMarket Activity Report & Daily Profit Focused Screening - newser.com
Can Kiora Pharmaceuticals Inc. stock resist market sell offsFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Will Kiora Pharmaceuticals Inc. stock outperform growth indexes2025 Biggest Moves & AI Powered Market Entry Strategies - newser.com
Why Kiora Pharmaceuticals Inc. (7EY) stock signals breakout potentialTrade Exit Summary & Expert Curated Trade Ideas - newser.com
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
4.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):